Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is operating in lab testing segment that is highly competitive and fragmented. Though it posted growth in its top and bottom lines for the reported periods, the sustainability of such margins going forward is a major concern. Based on its FY24 super earnings, the issue appears aggressively priced. There is no harm in skipping this pricey bet. Read detail review...
Qualitek Labs Limited peer comparison with similar listed entities. (As on March 31, 2023)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Qualitek Labs Limited | 5.49 | 5.49 | 24.74 | 18.21 | 30.10 | 4.04 | |
| Choksi Laboratories Ltd. | 4.69 | 11.74 | 6.58 |
Notes:
Qualitek Labs IPO Reviews, analysis and views by popular members. Read Qualitek Labs Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP